N8bio Shares Fall After Preclinical Data From Non-Signaling CAR Platform Targeting Cancer

 

• IN8bio Inc 
  INAB-11.1%+ Free Alerts
   announced the ability of its non-signaling gamma-delta CAR-T platform (nsCAR) to target leukemic cells while preserving healthy B cells selectively. 
• IN8bio's nsCAR platform uses the innate immune recognition of gamma-delta T cells to distinguish between tumor and healthy tissue, offering a targeted but potentially less toxic approach.
• In a 48-hour in vitro cytotoxicity experiment, the nsCAR platform demonstrated a greater than 15x difference in killing between leukemic cells and healthy B cells (79.7% versus 5.2%) when both express the CD19 target antigen.
• The nsCAR platform is also engineered to express the cytokine interleukin-15 (IL-15) to enhance cellular persistence and the ability to target and kill tumor cells over time. 
• The platform can potentially broaden CAR technology's utilization for previously "undruggable" solid and liquid tumor targets, the company said.

https://www.benzinga.com/general/biotech/23/02/31029598/in8bio-shares-fall-after-preclinical-data-from-non-signaling-car-platform-targeting-cancer-cells